Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes

Journal of Pediatric Hematology/Oncology

Volumn 21, Issue 2, 1999, Pages 91-102

  Martinez Climent, Jose A ^a   García Conde, Javier ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Children; Chromosomal abnormalities; Cytogenetics; Molecular analysis; Myelodysplastic syndrome; Myeloid leukemia

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 16; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REMISSION;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; ONCOGENE PROTEINS, FUSION; ONCOGENES; PATIENT CARE PLANNING; POLYPLOIDY; PROGNOSIS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 0342424184     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199903000-00004     Document Type: Article

References (182)

1. Pui C-H. Childhood leukemias. N Engl J Med 1995;332:1618-30.
2. Rowley JD. Recurring chromosome abnormalities in leukemia and lymphoma. Semin Hematol 1990;27:122-36.
3. Pui-CH, Campana D, Crist WM. Towards a clinically useful classification of acute leukemias. Leukemia 1995;9:2154-7.
4. Rubin CM, Rowley JD. Chromosomal abnormalities in childhood malignant diseases. In: Nathan DG, Oski FA, eds. Hematology of infancy and childhood. Philadelphia. PA: WB Saunders, 1993:1288-1318.
5. Rowley JD, Aster JC, Sklar J. The impact of new DNA diagnostic technology on the management of cancer patients. Arch Pathol Lab Med 1993;117:1104-9.
6. Martinez-Climent JA, Lane N, Rubin CM, et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia. Leukemia 1995;9:95-101.
7. Kalwinsky DK, Raimondi SC, Schell MJ, et al. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol 1990;8:75-86.
8. Leblanc T, Auvrignon A, Michel G, et al. Prognosis value of cytogenetics in 250 children with acute myeloblastic leukemia treated in the LAME 89/91 protocol [abstract 2524]. Blood 1996;88:10(Suppl 1):634aa.
9. Passmore S, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995;85:1742-50.
10. Wells R, Arndt CAS. New agents for treatment of children with acute myelogenous leukemia. J Pediatr Hematol Oncol 1995;17:225-33.
11. Rubin CM, LeBeau MM. Cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1991;13:202-16.
12. Bathia S, Neglia JP. Epidemiology of childhood acute myelogenous leukemia. J Pediatr Hematol Oncol 1995;17:94-100.
13. Taub JW, Ravindranath Y. Treatment of childhood acute myeloid leukemia. Baillieres Clin Haematol 1996;9:129-46.
14. Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. J Pediatr Hematol Oncol 1995;17:185-97.
15. Dinndorf P, Bunin N. Bone marrow transplantation for children with acute myelogenous leukemia. J Pediatr Hematol Oncol 1995;17:211-24.
16. Nesbit ME, Buckley JD, Feig SA, et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by bone marrow transplantation or multiagent chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1994;12:127-35.
17. Michel G, Leverger G, Leblanc T, et al. Allogeneic bone marrow transplantation vs. aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission: a prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 1996;17:191-6.
18. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996;334:1428-34.
19. Hurwitz CA, Schell MJ, Pui C-H, et al. Adverse prognostic features in 251 children treated for acute myelogenous leukemia. Med Pediatr Oncol 1993;21:1-7.
20. Raimondi SC, Kalwinsky DK, Hayashi Y, et al. Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1989;40:13-27.
21. Head DR. Revised classification of acute myeloid leukemia. Leukemia 1996;10:1826-31.
22. Martinez-Climent JA, Thirman MJ, Espinosa R III, et al. Detection of 11q23/MLL rearrangements in infant leukemias with fluorescence in situ hybridization and molecular analysis. Leukemia 1995;1299-1304.
23. Sorensen PHB, Chen C-S, Smith F, et al. Molecular rearrangements of the MLL gene are present in most cases of infant AML and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 1994;93:429-37.
24. Martinez-Climent JA, Espinosa R III, Thirman MJ, et al. Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias: identification of the t(9;11) as an indicator of long survival. J Ped Hematol Oncol 1995;17:277-83.
25. Barnard DR, Kalousek DK, Wiersma SR, et al. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: a report from the Childrens Cancer Group. Leukemia 1995;10:5-12.
26. Woods WG, Nesbit ME, Buckley J, et al. Correlation between chromosomal abnormalities with patient characteristics, histologic subtype, and induction success in children with acute nonlymphocytic leukemia. J Clin Oncol 1985;3:3-11.
27. Ritterbach J, Harbott J, Ritter J, et al. Chromosomal aberrations in childhood acute nonlymphoblastic leukemia. In: Buchner T. Schellong B. Hiddemann R, Ritter J, eds. Haematology and blood transfusions: Acute leukemias II. Vol 33. Berlin, Heidelberg: Springer-Verlag, 1990:153-6.
28. Avet-Loiseau H, Mechinaud F, Harousseau JL, et al. Clonal hematologic disorders in Down syndrome. J Pediatr Hematol Oncol 1995;17:19-24.
29. Litz CE, Davies S, Brunning RD, et al. Acute leukemia and the transient myeloproliferative disorder associated with Down syndrome: morphologic, immunophenotypic, and cytogenetic manifestations. Leukemia 1995;9:1432-9.
30. Jenkins RB, LeBeau MM, Kraker WJ, et al. Interphase fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood 1992;79:3307-15.
31. Zipursky A, Doyle J. Leukemia in newborn infants with Down syndrome. Leukemia Res 1993;17:195-9.
32. Gad SG, Callen DF, Kuss B, et al. Identification of an inversion 16 coexisting with an isochromosome 22q by in situ hybridization in a case of childhood AML M4Eo. Leukemia 1993;7:1658-62.
33. Suenaga M, Sanada I, Tsukamoto A, et al. Trisomy 4 in a case of acute myelogenous leukemia accompanied by subcutaneous soft tissue tumors: report of a case and review of the literature. Cancer Genet Cytogenet 1993;71:71-5.
34. LeBeau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlation in 63 patients with with therapy-related myelodysplastic syndrome and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes 5 and 7. J Clin Oncol 1986;4:325-45.
35. LeBeau MM, Espinosa III R, Davis EM, et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996;88:1930-5.
36. Shanon KM, Turhan AG, Rogers PC, et al. Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7. Genomics 1992;14:121-30.
37. Velloso ERP, Michaux L, Ferrant A, et al. Deletions of the long arm of chromosome 7 in myeloid disorders: loss of band 7q32 implies worst prognosis. Br J Haematol 1996;92:574-81.
38. Luna-Fineman S, Shannon K, Lange B. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood 1995;85:1985-99.
39. Hayashi Y, Hanada R, Yamamoto K. Chromosome abnormalities and prognosis in children with leukemia. Acta Paediatr Jpn 1991;33:497-506.
40. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 1996;10:1288-95.
41. Rowley JD. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973;16:109-12.
42. Leverger G, Bernheim A, Daniel M-T, et al. Cytogenetic study of 130 childhood acute nonlymphocytic leukemias. Med Pediatr Oncol 1988;16:227-32.
43. Prigonina El, Fleischman EW, Puchkova GP, et al. Chromosomes in acute nonlymphocytic leukemia. Human Genet 1986;73:137-46.
44. Gallego M, Carroll AJ, Gad GS, et al. Variant t(8;21) rearrangements in acute myeloblastic leukemia of childhood. Cancer Genet Cytogenet 1994;75:139-44.
45. Kwong YL, Ha SY, Ching LM, et al. Interstitial deletion of 9q revisited. Leuk Lymphoma 1993;12:153-5.
46. Bitter MA, LeBeau MM, Rowley JD, et al. Association between morphology, karyotype, and clinical features in myeloid leukemias. Human Pathol 1987;18:211-25.
47. Nucifora G, Dickstein JI, Torbenson V, et al. Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21). Leukemia 1994;8:1533-8.
48. Hurwitz CA, Raimondi SC, Head D, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992;80:3182-8.
49. Haas OA, Koller U, Grois N, et al. Immunophenotype of hematologic neoplasms with a translocation t(8;21): recent results. Cancer Res 1993;131:361-8.
50. Tallman MS, Hakimian D, Shaw JM, et al. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 1993;11:690-7.
51. Groupe Francais de Cytogenetique Hematologique. Acute myelogenous leukemia with an 8;21 translocation: a report of 148 cases from the Groupe Francaise de Cytogenetique Hematologique. Cancer Genet Cytogenet 1990;44:169-79.
52. Keating M, Smith T, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988;2:403-12.
53. Ravindranath Y, Chang M, Camitta B, et al. Prognostic factors in childhood acute myeloid leukemia (AML): Experience on Pediatric Oncology Group (POG) 8821 AML study [abstract 2385]. Blood 1995;86;599A.
54. Erickson P, Gao J, Chang K-S, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, Runt. Blood 1992;80:1825-31.
55. Nucifora G, Birn D, Erickson P, et al. Detection of DNA rearrangements in the AML-1 and ETO loci and of an AML-1/ETO fusion mRNA in patients with t(8;21) AML. Blood 1993;81:883-8.
56. Downing JR, Head DR, Curcio-Brint AM, et al. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 1993;81:2860-5.
57. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993;82:712-15.
58. Chang K-S, Fan Y, Stass SA, et al. Expression of the AML1/ETO fusion transcript and detection of minimal residual disease in t(8;21)-positive acute myelogenous leukemia. Oncogene 1993;8:983-8.
59. Erickson PF, Dessev G, Lasher RS, et al. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 1996;88:1813-23.
60. Muto A, Mori S, Matsushita H, et al. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukemia with RT-competitive PCR assay. Br J Haematol 1996;95:85-94.
61. Tobal K, Liu Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Blood 1996;88:3704-9.
62. Creutzig U, Ritter J, Zimmermann M, et al. Does cranial irradiation reduce the risk of bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol 1993;11:279-86.
63. Carter M, Kalwinsky DK, Dahl GV, et al. Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biological features. Leukemia 1989;3:298-302.
64. Biondi A, Rovelli A, Cantù-Rajnoldi A, et al. Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP). Leukemia 1994;8:1264-8.
65. Douer D, Preston-Martin S, Chang E, et al. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996;87:308-13.
66. Lemons RS, Keller S, Gietzen D, et al. Acute promyelocytic leukemia. J Pediatr Hematol Oncol 1995;17:198-210.
67. Larson RA, Kondo K, Vardiman JW, et al. Evidence of a t(15:17) translocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76:827-41.
68. Schoch C, Haase D, Haferlach T, et al. Incidence and implication of additional chromosome aberratons in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report of 50 cases. Br J Haematol 1996;94:493-500.
69. Hiorns L, Swansbury GJ, Mehta J, et al. Additional chromosome abnormalities confer a worse prognosis in acute promyelocytic leukemia. Br J Haematol 1997;96:314-21.
70. Brunel V, Lafage-Pochitaloff M, Alcalay M, et al. Variant and masked translocations in acute promyelocytic leukemia. Leak Lymphoma 1996;22:221-8.
71. Warrell RP, de The H, Wang ZY, et al. Acute promyelocytic leukemia. N Engl J Med 1993;329:177-89.
72. Feneaux P, Chomienne C. Biology and treatment of acute promyelocytic leukemia. Curr Opin Oncol 1996;8:3-12.
73. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans-retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995;85:1202-6.
74. de Thé H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990;347:558-61.
75. Borrow J, Goddard AD, Sheer D, et al. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249:1577-80.
76. Alcalay M, Zangrilli D, Pandolfi PP, et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci USA 1991;88:1977-81.
77. Lemons RS, Eilender D, Waldmann RA, et al. Cloning and characterization of the t(15;17) translocation breakpoint cluster region in acute promyelocytic leukemia. Genes Chromosomes Cancer 1990;2:79-87.
78. Alcalay M, Zangrilli D, Fagioli M, et al. Expression pattern of the RARA/PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992;89:4840-4.
79. Licht J, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995;85:1083-94.
80. Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as predictor of relapse in acute promyelocytic leukemia. Lancet 1992;340:1437-8.
81. Kane JR, Head DR, Balazs L, et al. Molecular analysis of the PML/RARA chimeric gene in pediatric acute promyelocytic leukemia. Leukemia 1996;10:1296-1302.
82. Zhao L, Chang K-S, Estey EH, et al. Detection of residual leukemic cells in patients with acute promyelocytic leukemia by the fluorescence in situ hybridization method: potential for predicting relapse. Blood 1995;85:495-9.
83. LeBeau MM, Larson RA, Bitter MA, et al. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. N Engl J Med 1983;309:630-6.
84. Campbell LJ, Challis J, Fox T, et al. Chromosome 16 abnormalities associated with myeloid malignancies. Genes Chromosomes Cancer 1991;3:55-61.
85. Adriaansen HJ, te Boekhorst PAW, Hagemeijer AM, et al. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(pl3q22) exhibits a specific immunophenotype with CD2 expression. Blood 1993;81:3043-51.
86. Martinez-Climent JA, Comes AM, Vizcarra E, et al. Variant three-way translocation of inv(16) in AML-M4eo confirmed by fluorescence in situ hybridization analysis. Cancer Genet Cytogenet 1999; in press.
87. Holmes R, Keating MJ, Cork A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985;65:1071-8.
88. Larson RA, Williams SF, Le Beau MM, et al. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood 1986;68:1242-9.
89. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBFB/PEBP2B and a myosin heavy chain in acute myeloid leukemia. Science 1993;261:1041-4.
90. Claxton DF, Liu P, Hsu HB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 1994;83:1750-6.
91. Claxton D, Xie Q-S, Patel S, et al. The gene product of CBFB-MYH11. Leukemia 1996;10:1479-85.
92. Liu PP, Hajra A, Wijmenga C, et al. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 1995;85:2289-2302.
93. Marlton P, Claxton DF, Liu P, et al. Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis. Blood 1995;85:772-9.
94. Shurtleff SA, Meyers S, Hiebert SW, et al. Heterogeneity in CBFB-MYH11 fusion messages encoded by the inv(16)(p13q22) or t(16;16)(p13;q22) in acute myelogenous leukemia. Blood 1995;85:3695-703.
95. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodological advances and clinical significance. Blood 1995;6:1416-34.
96. Poirel H, Radford-Weiss I, Rack K, et al. Detection of chromosome 16 CBFB-MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995;85:1313-22.
97. Evans PAS, Short MA, Jack AS, et al. Detection and quantitation of the CBFB/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML. Leukemia 1997;11:364-9.
98. Rowley JD. Rearrangements involving chromosome band 11q23 in acute leukemia. Semin Cancer Biol 1993;4:377-85.
99. Rubnitz JE, Behm FG, Downing JR. 11q23 rearrangements in acute leukemia. Leukemia 1994;10:74-82.
100. Rowley JD, Diaz MO, Espinosa III R, et al. Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: identification of 11q23 translocation breakpoints with a yeast artificial chromosome. Proc Natl Acad Sci USA 1990;87:9358-62.
101. Ziemin-Van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 1991;88:10735-9.
102. Thirman MJ, Gill HJ, Bumett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993;329:909-14.
103. Cimino G, Rapanotti MC, Elia L, et al. ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French-American-British classification subtypes and young age. Cancer Res 1995;55:1625-8.
104. Bower M, Parry P, Carter M, et al. Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/M5. Blood 1995;84:3776-80.
105. Pui C-H, Raimondi SC, Head DR, et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991;78:1327-37.
106. Rubin CM, Arthur DC, Woods WG, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood 1991;78:2982-8.
107. Pui C-H, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7.
108. Smith FO, Howells WB, Buckley JD, et al. Prognostic factors (PF) in children with acute myeloid leukemia (AML): results of childrens cancer group (CCG) protocol 2891 [abstract 2498]. Blood 1997;90:561A.
109. Heim S, Avanzi GC, Billström R, et al. A new specific chromosomal rearrangement t(8;16)(p11;p13) in acute monocytic leukemia. Br J Haematol 1987;66:323-6.
110. Lai JL, Zandecki M, Jouet JP, et al. Three cases of translocation (8;16)(p11;p13) observed in acute myelomonocytic leukemia: a new specific subgroup? Cancer Genet Cytogenet 1987;27:101-9.
111. Hanslip JL, Swansbury JGJ, Pinkerton R, et al. The translocation t(8;16)(p11;p13) defines an AML subtype with distinct cytologic and clinical features. Leuk Lymphoma 1992;6:479-86.
112. Liso V, Specchia G, Capalbo S, et al. Cytophagocytosis by the blast cells in acute myeloid leukemia. Leuk Lymphoma 1995;18(Suppl 1):65-8.
113. Rodrigues Pereira Velloso E, Mecucci C, Michaux L, et al. Translocation t(8;16)(p11;p13) in acute nonlymphocytic leukemia: report on two new cases and review of the literature. Leuk Lymphoma 1996;21:137-42.
114. Schouten TJ, Hustinx TWJ, Scheres JMJC, et al. Malignant histiocytosis: clinical and cytogenetic studies in a newborn and in a child. Cancer 1983;52:1229-36.
115. Bernstein R, Pinto MR, Spector I, et al. A unique 8;16 translocation in two infants with poorly differentiated monoblastic leukemia. Cancer Genet Cytogenet 1987;24:213-20.
116. Smajda N, De Gramont A, Gonzalez-Canali G, et al. Another case of acute myelomonocytic leukemia with t(8;16)(p11;p13). Cancer Genet Cytogenet 1988;36:137-9.
117. Zandecki M, Lai JL, Mazingue F, et al. Congenital acute monoblastic leukemia with doble translocation (8;16)(p11;p13) and (16;20)(q13:p13). Nouv Rev Fr Hematol 1988;30:247-50.
118. Hanada T, Ono I, Minosaki Y, et al. Translocation t(8;16)(p11;p13) in neonatal acute monocytic leukemia. Eur J Pediatr 1991;150:323-4.
119. Borrow J, Stanton VP Jr, Andressen JM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukemia fuses a putative acetyltransferase gene to the CREB-binding protein. Nature Genet 1996;14:33-41.
120. Rowley JD, Potter D. Chromosomal banding pattern in acute nonlymphocytic leukemia. Blood 1976;47:705-21.
121. Lillington DM, MacCallum PK, Lister TA, et al. Translocation t(6;9)(p23;q34) in acute myeloid leukemia without myelodysplasia or basophilia: two cases and review of the literature. Leukemia 1993;7:527-31.
122. Soekarman D, von-Lindern M, Daenen S, et al. The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood 1992;79:2990-7.
123. Pearson MG, Vardiman JW, LeBeau MM, et al. Increased numbers of marrow basophils may be associated with a t(6;9) in ANLL. Am J Hematol 1985;18:393-403.
124. Fonatsch C, Stollmann B, Holldack J, et al. Translocation t(6;9)p23;q34) in smoldering leukemia and acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1987;26:363-8.
125. Cuneo A, Kerim S, Vandenbergue E, et al. Translocation t(6;9) occurring in acute myelofibrosis, myelodysplastic syndrome, and acute nonlymphocytic leukemia suggests multipotent stem cell involvement. Cancer Genet Cytogenet 1989;42:209-19.
126. Sandberg AA, Morgan R, MacCallister JA, et al. Acute myeloblastic leukemia with t(6;9)(p23;q34): a specific subgroup of AML? Cancer Genet Cytogenet 1983;10:139-42.
127. Carroll AJ, Castleberry RP, Prchal JF, et al. Translocation t(6;9)(p23;q34) in acute nonlymphocytic leukemia: three new cases. Cancer Genet Cytogenet 1985;18:303-6.
128. Heim S, Kristoffersson U, Mandahl N, et al. High resolution banding analysis of the reciprocal translocation t(6;9) in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1986;22:195-201.
129. Adriaansen HJ, van Dongen JJM, Hooijkaas H, et al. Translocation (6;9) may be associated with a specific TdT-positive immunological phenotype in ANLL. Leukemia 1988;2:136-40.
130. Stejkalova E, Goetz P, Stary J. A translocation (6;9)(p23;q34) and trisomy 13 in a case of childhood acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1990;45:139-41.
131. Westbrook CA, LeBeau MM, Diaz MO, et al. Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia. Proc Natl Acad Sci USA 1985;82:8742-6.
132. von Lindern M, Fornerod M, van Baal S, et al. The translocation t(6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, DEK and CAN, and the expression of a chimeric, leukemia-specific DEK-CAN mRNA. Mol Cell Biol 1992;12:1687-97.
133. Boer J, Mahmoud H, Raimondi SC, et al. Loss of DEK-CAN fusion transcript in a child with t(6;9) acute myeloid leukemia following chemotherapy and allogeneic bone marrow transplantation. Leukemia 1997;11:299-300.
134. Malkin D, Freedman MH. Childhood erythroleukemia: review of clinical and biological features. Am J Ped Hematol Oncol 1989;11:348-59.
135. Cuneo A, van Orshhoven A, Michaux JL, et al. Morphologic, immunologic, and cytogenetic studies in erythroleukemia: evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types. Br J Haematol 1990;75:346-54.
136. Olopade O, Thangavelu M, Larson RA, et al. Clinical, morphologic, and cytogenetic characteristics of 26 patients with erythroblastic leukemia. Blood 1992;80:2873-82.
137. Oliveira MH, Gonzaga L, Martelli LR, et al. Cytogenetic study of a case of childhood erythroleukemia. Cancer Genet Cytogenet 1990;49:25-30.
138. Shitara T, Yugami S-I, Sotomatu M, et al. Erythroleukemia in a child associated with monosomy 7. Cancer 1991;68:540-2.
139. Brodeur GM, Williams DL, Kalwinsky DK, et al. Cytogenetic features of acute nonlymphocytic leukemia in 73 children and adolescents. Cancer Genet Cytogenet 1983;8:93-105.
140. Stamberg J, Zaslav A, Shende A, et al. Simultaneous study of karyotype and cell morphology in childhood erythroleukemia. Am J Hematol 1988;27:284-90.
141. Stamberg J. Chromosome abnormalities in erythroleukemia. Cancer 1987;60:2649-53.
142. Kadam PR, Balsara BR, Zafaraullah KZ, et al. Cytogenetic features of erythroleukemia (EL). Cancer Genet Cytogenet 1990;50:89-96.
143. Nakamura H. Cytogenetic heterogeneity in erythroleukemia defined as M6 by the French - American - British (FAB) Cooperative Group criteria. Leukemia 1989;3:305-9.
144. Hagemeijer A, van Zanen GE, Smit EM, et al. Bone marrow karyotypes of children with nonlymphocytic leukemia. Pediatr Res 1979;13:1247-54.
145. Morse H, Hays T, Peakman D, et al. Acute nonlymphoblastic leukemia in childhood: high incidence of clonal abnormalities and nonrandom changes. Cancer 1979;44:164-70.
146. Fitgerald PH, Morris CM, Fraser GJ, et al. Nonrandom cytogenetic changes in New Zealand patients with acute myeloid leukemia. Cancer Genet Cytogenet 1983;8:51-66.
147. Douglas EC, Freeman DL. Hypotetraploidy in erythroleukemia. Cancer Genet Cytogenet 1983;8:231-4.
148. Windebank KP, Tefferi A, Smithson WA, L, et al. Acute megakaryoblastic leukemia (M7) in children. Mayo Clin Proc 1989;64:1339-51.
149. Martinez-Climent JA, Ferris J, Esquembre C, et al. Acute megakaryoblastic leukemia in infants. An Esp Pediatr 1993;38:545-9.
150. Lu G, Altman AJ, Benn PA. Review of the cytogenetic changes in acute megakaryoblastic leukemia: one disease or several? Cancer Genet Cytogenet 1993;67:81-9.
151. Zipursky A, Thorner P, De Harven E, et al. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leukemia Res 1994;18:163-71.
152. Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome: a report of 40 children of the AML-BFM Study group. Leukemia 1996;10:1677-86.
153. Suarez CR, LeBeau MM, Silberman S, et al. Acute megakaryoblastic leukemia in Down's syndrome: report of a case and review of cytogenetic findings. Med Pediatr Oncol 1985;13:225-31.
154. Ravindranath Y, Abella B, Krischer JP, et al. Acute myeloid leukemia in Down's syndrome is highly responsive to chemotherapy: experience on the Pediatric Oncology AML Group study 8498. Blood 1992;80:2210-14.
155. Sait SNJ, Brecher ML, Green DM, et al. Translocation t(1;22) in congenital acute megakaryoblastic leukemia. Cancer Genet Cytogenet 1988;34:277-80.
156. Carroll AJ, Civin C, Schneider N, et al. The t(1;22)(p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a pediatric oncology group study. Blood 1991;78:748-52.
157. Lion T, Haas OA, Harbott J, et al. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood 1992;80:3325-30.
158. Baruchel A, Daniel MT, Schaison G, et al. Nonrandom t(1;22)(p12-p13;q13) in acute megakaryocytic malignant proliferation. Cancer Genet Cytogenet 1991;54:239-43.
159. Washio S, Ido M, Azuma E, et al. Acute megakaryoblastic leukemia with translocation t(1:22)(p13:q13) in a ten-week-old infant. Am J Hematol 1992;39:56-60.
160. Ashfaq R, Weinberg AG, Argyle CA. Acute megakaryoblastic leukemia simulating carcinoma. Am J Clin Pathol 1992;98:55-60.
161. Chan WC, Carroll A, Alvarado CS, et al. Acute megakaryoblastic leukemia in infants with t(1;22)(p13;q13). Am J Clin Pathol 1992;98:214-21.
162. Lion T, Haas O. Acute megakaryoblastic leukemia with the t(1;22)(p13;q13). Leuk Lymphoma 1993;11:15-20.
163. Bitter MA, Neilly ME, LeBeau MM, et al. Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia. Blood 1985;66:1362-70.
164. Hasle H. Myelodysplastic syndromes in childhood: classification, epidemiology, and treatment. Leuk Lymphoma 1994;13:11-26.
165. Haas O, Gadner H. Pathogenesis, biology, and management of myelodysplastic syndromes in children. Semin Hematol 1996;33:225-35.
166. Creutzig U, Cantú-Rajnoldi A, Ritter J, et al. Myelodysplastic syndromes in children: report of 21 patients from Italy and West Germany. Am J Ped Hematol Oncol 1987;9:324-30.
167. Brandwein JM, Horsman DE, Eaves AC, et al. Childhood myelodysplasia: suggested classification as myelodysplastic syndromes based on laboratory and clinical findings. Am J Ped Hematol Oncol 1990;12:63-70.
168. Jackson GH, Carey PJ, Cant AJ, et al. Myelodysplastic syndromes in children. Br J Haematol 1993;84:185-6.
169. Tuncer MA, Pagliuca A, Hicsonmez G, et al. Primary myelodysolastic syndrome in children: the clinical experience in 33 cases. Br J Haematol 1993;82:347-53.
170. Locatelli F, Zecca M, Pession A, et al. Myelodysplastic syndromes: the pediatric point of view. Haematologica 1995;80:268-79.
171. Wegelius R. Bone marrow dysfunctions preceding acute leukemia in children: a clinical study. Leukemia Res 1992;16:71-6.
172. Jotterand M, Parlier V. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leuk Lymphoma 1996;23:253-66.
173. Feneaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin Hematol 1996;33:127-38.
174. Haasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 1995;9:1569-72.
175. Chan GCF, Wang WC, Raimondi SC, et al. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Leukemia 1997;11:206-11.
176. Hasle H, Arico M, Basso G, et al. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) associated with complete or partial monosomy 7: an EWOG-MDS study of 110 children [abstract 2325]. Blood 1996;88:10(Suppl 1):584aa.
177. Baranger L, Baruchel A, Leverger G, et al. Monosomy 7 in childhood hemopoietic disorders. Leukemia 1990;4:345-9.
178. Sieff CA, Chessells JM, Harvey BAM, et al. Monosomy 7 in childhood: a myeloproliferative disorder. Br J Haematol 1981;49:235-41.
179. Butcher M, Frenck R, Emperor J, et al. Molecular evidence that childhood monosomy 7 syndrome is distinct from juvenile chronic myelogenous leukemia and other childhood myeloproliferative disorders. Genes Chromosomes Cancer 1995;12:50-7.
180. Hasle H, Kerndrup G, Yssing M, et al. Intensive chemotherapy in childhood myelodysplastic syndrome: a comparison with results in acute myeloid leukemia. Leukemia 1996;10:1269-73.
181. Sandoval C, Pui CH, Bowman LC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 1993;11:1039-45.
182. Rowley JD, Reshmi S, Sobulo O, et al. All patients with t(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997;90:535-41.